HRP20181343T1 - Postupci i pripravci za induciranje imunosnog odgovora na egfrviii - Google Patents

Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Info

Publication number
HRP20181343T1
HRP20181343T1 HRP20181343TT HRP20181343T HRP20181343T1 HR P20181343 T1 HRP20181343 T1 HR P20181343T1 HR P20181343T T HRP20181343T T HR P20181343TT HR P20181343 T HRP20181343 T HR P20181343T HR P20181343 T1 HRP20181343 T1 HR P20181343T1
Authority
HR
Croatia
Prior art keywords
egfrviii
preparations
procedures
immune response
inducing immune
Prior art date
Application number
HRP20181343TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter M. Lauer
Keith Bahjat
Original Assignee
Aduro Biotech, Inc.
Providence Health & Services-Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Inc., Providence Health & Services-Oregon filed Critical Aduro Biotech, Inc.
Publication of HRP20181343T1 publication Critical patent/HRP20181343T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20181343TT 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii HRP20181343T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii
EP11841347.5A EP2640842B1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (1)

Publication Number Publication Date
HRP20181343T1 true HRP20181343T1 (hr) 2018-10-19

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181343TT HRP20181343T1 (hr) 2010-11-17 2011-11-17 Postupci i pripravci za induciranje imunosnog odgovora na egfrviii

Country Status (17)

Country Link
US (3) US9200057B2 (enExample)
EP (1) EP2640842B1 (enExample)
JP (1) JP5998370B2 (enExample)
CN (1) CN103415620B (enExample)
CA (1) CA2818353A1 (enExample)
CY (1) CY1120622T1 (enExample)
DK (1) DK2640842T3 (enExample)
ES (1) ES2684684T3 (enExample)
HR (1) HRP20181343T1 (enExample)
HU (1) HUE039747T2 (enExample)
LT (1) LT2640842T (enExample)
PL (1) PL2640842T3 (enExample)
PT (1) PT2640842T (enExample)
RS (1) RS57630B1 (enExample)
SI (1) SI2640842T1 (enExample)
SM (1) SMT201800444T1 (enExample)
WO (1) WO2012068360A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
AU2015250111A1 (en) * 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MA44378A (fr) * 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
KR20180002640A (ko) * 2015-04-13 2018-01-08 아두로 바이오테크, 인코포레이티드 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
MA43362A (fr) * 2015-05-26 2018-10-10 Advaxis Inc Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations
MA42263A (fr) * 2015-06-24 2021-03-31 Advaxis Inc Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN109890834A (zh) * 2016-08-01 2019-06-14 艾杜罗生物科技公司 蛋白质表达增强子序列及其用途
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
EP2860253B1 (en) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
WO2009012488A1 (en) * 2007-07-19 2009-01-22 Duke University Assay for human anti-egrf variant iii antibodies
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII

Also Published As

Publication number Publication date
WO2012068360A1 (en) 2012-05-24
HUE039747T2 (hu) 2019-02-28
EP2640842A1 (en) 2013-09-25
CN103415620A (zh) 2013-11-27
SI2640842T1 (sl) 2018-09-28
RS57630B1 (sr) 2018-11-30
US20160074491A1 (en) 2016-03-17
US9775891B2 (en) 2017-10-03
US20140037662A1 (en) 2014-02-06
EP2640842B1 (en) 2018-05-30
EP2640842A4 (en) 2014-04-09
SMT201800444T1 (it) 2018-09-13
DK2640842T3 (en) 2018-08-13
ES2684684T3 (es) 2018-10-04
CA2818353A1 (en) 2012-05-24
LT2640842T (lt) 2018-09-10
PT2640842T (pt) 2018-10-12
JP5998370B2 (ja) 2016-09-28
CN103415620B (zh) 2016-10-12
US9200057B2 (en) 2015-12-01
CY1120622T1 (el) 2019-12-11
US20180021420A1 (en) 2018-01-25
PL2640842T3 (pl) 2018-11-30
JP2014504851A (ja) 2014-02-27

Similar Documents

Publication Publication Date Title
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
HUE039747T2 (hu) Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
PL2580243T3 (pl) Przeciwciała przeciwko ludzkiemu CD38
IL229663A0 (en) Algal lipid compositions and methods of preparing and utilizing same
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
SMT201900181T1 (it) Metodi di preparazione di coniugati
HUE045656T2 (hu) PHF-tau elleni ellenanyagok és alkalmazásuk
DK2914633T3 (da) Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2598120A4 (en) COMPOSITIONS AND METHOD FOR CREATING AN IMMUNO TOLERANCE
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
LT2776469T (lt) Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PT3462173T (pt) Anticorpos contra risperidona e utilização dos mesmos
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
EP2931313A4 (en) Solution Formulations of Genetically Engineered Anti- 23P19 Antibodies
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
IL225389A0 (en) Antibody compositions and methods of use
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
CR20130375A (es) Preparaciones que contienen antraquinona/formulaciones de lignina
PL2908833T3 (pl) Preparaty zawierające wyciągi ziołowe
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS